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Abstract
Genome-wide siRNA screens have identified host cell factors important for efficient HIV infection, among which are nuclear
pore proteins such as RanBP2/Nup358 and the karyopherin Transportin-3/TNPO3. Analysis of the roles of these proteins in
the HIV replication cycle suggested that correct trafficking through the pore may facilitate the subsequent integration step.
Here we present data for coupling between these steps by demonstrating that depletion of Transportin-3 or RanBP2 altered
the terminal step in early HIV replication, the selection of chromosomal sites for integration. We found that depletion of
Transportin-3 and RanBP2 altered integration targeting for HIV. These knockdowns reduced HIV integration frequency in
gene-dense regions and near gene-associated features, a pattern that differed from that reported for depletion of the HIV
integrase binding cofactor Psip1/Ledgf/p75. MLV integration was not affected by the Transportin-3 knockdown. Using
siRNA knockdowns and integration targeting analysis, we also implicated several additional nuclear proteins in proper
target site selection. To map viral determinants of integration targeting, we analyzed a chimeric HIV derivative containing
MLV gag, and found that the gag replacement phenocopied the Transportin-3 and RanBP2 knockdowns. Thus, our data
support a model in which Gag-dependent engagement of the proper transport and nuclear pore machinery mediate
trafficking of HIV complexes to sites of integration.
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Introduction
To complete the early steps of infection, retroviral preintegation
complexes (PICs) must access the nucleus of the infected cell and
integrate the viral cDNA into host chromatin. Gammaretroviruses
such as MLV require nuclear envelope breakdown during mitosis
to access cellular chromosomes and complete integration [1,2]. In
contrast, lentiviruses such as HIV can enter the nucleus in non-
cycling cells, presumably by traversing the nuclear pore [3–5].
Passage through the pore is likely a preferred route of nuclear
entry for HIV-1 even in dividing cells – several components of the
nuclear pore are required for efficient infection of dividing cells,
even though PICs might access the nucleus during nuclear
breakdown in mitosis [6–11]. Moreover, in infections initiated
during interphase, integration occurs before mitosis, while
integration in cells infected just prior to mitosis is delayed until
the following interphase [12]. These data suggest that the steps of
HIV import through the nuclear pore may be coupled to
subsequent integration. In support of this hypothesis, Ko¨nig and
colleagues found that in dividing cells depleted of some nuclear
pore factors or karyopherins, HIV DNA entered the nucleus but
did not integrate efficiently [7]. Thus the route of nuclear entry
may influence subsequent integration, and the pore may provide
the preferred route even in dividing cells.
Retroviral integration is known to be modulated by several host
components. Integration target site selection is guided by the
genomic environment of the integration acceptor site [13–18].
Lentiviruses such as HIV show a preference for integration in
active transcription units, which may promote efficient expression
after integration [13,19–21]. Gammaretroviruses such as MLV
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show a preference for integration near gene 59 ends and CpG
islands [13–15]. Target site preferences of HIV integration are due
in part to tethering by a host chromatin binding protein, Ledgf/
p75 (product of the PSIP1 gene), which binds lentiviral IN [22,23]
and mediates IN-chromatin binding [24,25]. In the absence of
Ledgf/p75, HIV integration is severely compromised and
integration in transcription units is diminished [26–28]. Recently,
the tethering model for Ledgf/p75 function was bolstered by the
finding that fusion proteins containing the IN-binding domain of
Ledgf/p75 fused to alternative chromatin binding domains
retargeted lentiviral integration efficiently [29–31].
Here we analyze host factors identified in genome-wide siRNA
screens [6–8] and find links between transport into the nucleus and
subsequent integration targeting. We chose factors whose
depletion, like that of Ledgf/p75, led to an infection block at
nuclear entry or integration. We initially surveyed effects of
knocking down expression of ten genes, then focused on two of
them, TNPO3 and RANBP2, which encode components of the
nuclear pore and import machinery. TNPO3 encodes Transpor-
tin-3, a karyopherin [32] that has been shown to be required for
import of HIV PICs into the nucleus in cycling cell lines and
macrophages [6,7,9]. RanBP2 (originally named Nup358), is a
large cyclophilin-related nuclear pore protein involved in the Ran-
GTPase cycle that orchestrates much of nuclear import and export
[33], and is also required for import of HIV PICs [7]. Recently,
Lee and colleagues isolated a capsid mutant (N74D) [34] that
bypassed the requirement for Transportin-3 and RanBP2, but
acquired a requirement for other nuclear pore factors. HIV capsid
had previously been suggested to be a viral determinant of nuclear
entry [35] and these data suggest a possible direct interaction of
capsid with Transportin-3 and RanBP2.
Using RNA interference, we reduced the expression of
candidate genes, confirmed that HIV titer was reduced as a
result, and then investigated the distribution of integration sites in
the human genome using DNA bar coding and 454/Roche
pyrosequencing. As controls, we studied infections and targeting
by MLV. We also studied integration targeting by a derivative of
HIV containing the gag gene (encoding the capsid structural
proteins) of MLV. We found that depletion of Transportin-3 and
RanBP2 resulted in marked alterations in the distribution of HIV
integration sites, providing a link between nuclear entry and
integration targeting. MLV integration patterns were not altered
in Tranportin-3 knockdowns, and substitution of MLV Gag into
HIV phenocopied the effects of the knockdowns. Several
additional host gene products were also identified as candidate
members of the pathway. Thus we can begin to specify a "railroad
track" through the nuclear pore to favored sites of HIV DNA
integration.
Results
Surveying integration site distributions after siRNA
knockdown
We initially analyzed 10 genes previously implicated as HIV
cofactors at or near the integration step to determine whether they
had effects on integration targeting (Table S1). We selected NUP98
[7,11], MAP4 [6,7], IK [7], ANAPC2 [7,8], PRPF38A [7],
RANBP2 [6,7], SNW1 [7], and TNPO3 [6,7] from siRNA screens,
and two other genes, WDR46 and WDHD1, the products of which
bind Ledgf/p75 in yeast two-hybrid screens (unpublished data). For
each gene, we tested several different siRNAs in HEK-293T cells.
Reduction of mRNA levels was confirmed by quantitative RT-PCR
(Figure S1), and we assessed inhibition of infection by a VSVG-
pseudotyped GFP reporter virus, as defined as percent of cells
expressing the GFP marker 48 h after infection (Figure S2), as well
as toxicity of the siRNAs (Figure S3). Selected knockdowns were
verified by Western blot (Figure S4 and Figure 1A).
This initial scan showed robust effects on infection efficiency for
the nuclear import factors Transportin-3 and RanBP2, confirming
observations from earlier studies [6,7,9,34]; therefore, these genes
were studied in detail as described in the following sections.
Results for Transportin-3 and RanBP2 have been corroborated by
further studies using stable knockdowns with shRNAs in HeLa
cells that achieved efficient reductions in mRNA levels (Schaller
et al., submitted). The remaining 8 genes were also analyzed for
integration targeting using our high throughput pipeline. We
return to findings for this group of genes at the end of the Results.
HIV integration site selection is modified by depletion of
Transportin-3 and RanBP2
Having confirmed that knockdown of Transportin-3 and
RanBP2 reduced the efficiency of HIV infection (Figure S2), we
examined the effect of these factors on integration site selection
using ligation-mediated PCR and 454-pyrosequencing as previ-
ously described [36]. Recovered genomic sequences were mapped
to the human genome draft hg18. Association of integration sites
with genomic features was then assessed (e. g. Figure 1B).
In the human genome, many types of features are linked–for
example, gene dense regions are rich in CpG islands and DNAseI
sites, high in G/C content, and rich in highly expressed genes
[37,38]. As a first step in illustrating the results, we present
integration site distributions as a function of gene density. In cells
depleted of Transportin-3 or RanBP2, the distribution of HIV
integration sites was altered towards regions of lower gene density
in comparison to control cells treated with siGL2, which targets
firefly luciferase GL2, a gene not found in the HEK-293T cells
(Figure 1C). The trend towards integration in less gene dense
regions was significant for both RANBP2 and TNPO3 knock-
downs (p,0.001, see below). There was no evidence of a bimodal
distribution integration sites with respect to gene density, which
would have suggested knockdown of the factors in only a portion
of the cells (Figure 1C).
The average gene density in a one megabase window
surrounding integration sites in cells depleted of either Transpor-
tin-3 or RanBP2 is plotted in Figure 1D. For comparison, matched
random control sites within the human genome were computa-
Author Summary
HIV continues to be responsible for approximately two
million deaths worldwide each year. As part of the viral
replication cycle, the viral cDNA is transported through the
nuclear pore into the nucleus where it integrates into the
host cell genome. HIV integrates non-randomly, likely
choosing integration sites within the host chromosomes
that best enable the viral genes to be expressed and,
ultimately, progeny virus to be produced. HIV uses host
factors to guide its selection of integration sites. Here we
demonstrate that components of the nuclear trafficking
and nuclear pore machinery are required for HIV to achieve
its normal pattern of integration sites. This finding
suggests that passage of the virus through the nuclear
pore into the nucleus is coupled to downstream integra-
tion events and enables the virus to achieve its final
position within the host genome. Our study provides new
insights into two important steps of the HIV replication
cycle and suggests possible new targets for anti-retroviral
drugs.
Transportin-3 and RanBP2 in HIV Integration
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tionally generated and are shown in black (described in [14,18]
and Text S1). The average gene density at integration sites in the
RANBP2 and TNPO3 knockdown cells was reduced compared to
cells treated with siGL2, though it remained higher than would be
expected for random integration. Thus integration in gene dense
regions is promoted in part by RanBP2 and Transportin-3. As a
control for the fact the knockdowns diminished infection, we
investigated whether infections at low MOI altered the distribution
of integration sites, but MOI was not found to affect integration
targeting detectably (data not shown).
Figure 1. Effects of siRNA treatments on HIV integration in gene dense regions. Cells were transfected with individual siRNAs or an siRNA
pool of four siRNAs targeting the same gene as indicated, and infected 48 hr later for an additional period of 48 hr prior to integration site analysis.
(A) Reduction in Transportin-3 and RanBP2 protein levels after RNAi. Protein abundance was measured at the time of infection by Western blot with
b-tubulin as a loading control. For comparison, protein levels are shown in cells treated with an siRNA against firefly luciferase (GL2), a gene not found
in HEK-293T cells. (B) Overview of the approach for integration site analysis. The number of genomic features of interest (blue bars), such as
transcription units, is tabulated within genomic intervals (black bars) surrounding integration sites (red arrowheads) or computationally-generated
matched random control sites (green arrowheads). The average number of times the genomic feature occurs within that window can be compared
across datasets. (C) Histogram indicating distribution of integration sites with respect to gene density. Cells were transfected with individual siRNAs
and infected as above. Sample names in legend indicate the gene targeted followed by the individual siRNA number. The number of genes in 1 Mb
windows surrounding each integration site was counted as in 1B. Integration sites in each dataset were binned (along the X-axis) according to the
number of genes within 1 MB interval surrounding each site. Curves were computed from histogram plot using Gaussian kernal density estimates. (D)
Barplot of the average number of RefSeq genes in 1 Mb windows surrounding sites of HIV integration or computationally generated matched
random controls. Mock transfected cells (no RNAi) and cells treated with the siRNA targeting luciferase GL2 (siGL2) are shown as controls. Asterisks
denote significant difference from control GL2 siRNA treated cells as determined by the nonparametric Mann–Whitney test (*P,0.05; **P,0.01;
***P,0.001).
doi:10.1371/journal.ppat.1001313.g001
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Figure 2. Effects of Transportin-3 and RanBP2 depletion on integration near multiple chromosomal features. Genes targeted by siRNA
in infected cells including the control, GL2, are shown above the columns. Mock cells received no siRNA. The genomic features analyzed are shown in
the rows and labeled on the left. Relationships between integration frequency and feature density are summarized using ROC curve areas [18], where
increasing shades of blue indicate a negative correlation with integration frequency and increasing shades of red indicate a positive correlation with
integration frequency relative to matched random control distributions. The control GL2 siRNA set was used for pairwise statistical comparisons
(overlay dashes). P values summarizing the significance of the departure from the GL2 control are shown with asterisks (*P,0.05; **P,0.01;
***P,0.001). Note that the asterisks and the heat map summarize different comparisons (to siGL2 and matched random controls, respectively). The
base pair values in the row labels indicate the size of the genomic interval used for analysis–often the most appropriate interval is not known, so
several different interval sizes are compared. A more detailed guide to the data presented in this figure can be found in Text S1. An interactive version
of this figure is available as Figure S5.
doi:10.1371/journal.ppat.1001313.g002
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Analysis of integration frequency relative to a large collection of
genomic features (described in Text S1) showed a common set of
changes in both the Transportin-3 and RanBP2 depleted cells
relative to the controls (Figure 2 and Figure S5). The reduction in
integration in gene dense regions was significant for both TNPO3
and RANBP2 knockdowns when analyzed over multiple genomic
intervals of different lengths. Significant differences were also seen
when only expressed genes (identified by Affymetrix chip transcrip-
tional profiling) were considered in a similar analysis (labeled
‘‘Expression Intensity’’ in Figure 2). Genomic features that correlate
with gene density such as DNase I hypersensitive sites and CpG
islands were similarly enriched near control HIV integration sites but
less enriched near sites from TNPO3 and RANBP2 knockdown cells.
GC-rich regions, normally favored by HIV [13], were disfavored in
most window sizes in the Transportin-3 and RanBP2 knockdowns.
By contrast, gene density at integration sites was not significantly
affected in Ledgf/p75 knockdowns compared to the control. The
GC content and the density of CpG islands within one kb of
integration sites actually increased in Ledgf/p75-depleted cells [26–
28], indicating divergent effects on integration targeting. Integration
within genes, which is reproducibly diminished in Ledgf/p75-
depleted cells [26–28], was not affected by TNPO3 knockdown, and
showed only a slight decrease in the RANBP2 knockdown cells.
Together these data suggest that Transportin-3 and RanBP2
influence HIV integration targeting relative to a collection of
features associated with gene dense regions, and do so in a manner
that differs from Ledgf/p75 tethering.
Effect of Transportin-3 depletion on integration site
selection can be partially rescued by expression from an
siRNA insensitive TNPO3 allele
Multiple different siRNAs directed against TNPO3 and RANBP2
mRNAs yielded similar effects on integration targeting that were not
observed in control knockdowns, indicating that off-target effects
were unlikely to explain the observed alterations in integration
targeting. As an additional control, we analyzed complementation of
the Transportin-3 depletion using a plasmid-encoded siRNA-
insensitive allele generated by site-directed mutagenesis of the
siRNA target sequence. The RANBP2 coding region is very large
(11,711 bp), and so rescue experiments were not attempted for this
factor. Co-transfection of the resistant Transportin-3 expression
vector with the corresponding siRNA resulted in overexpression of
Transportin-3 and restored HIV infection, increasing reporter virus
GFP expression above control levels (Figure 3a and b).
We observed an increase in gene density near integration sites in
knockdown cells co-transfected with the siRNA-insensitive
TNPO3 allele compared to vector-only controls (Figure 3c and
Figure S6). The average number of genes within 1 Mb of HIV
Figure 3. Transfection of a Transportin-3 allele insensitive to
TNPO3 si4 restores protein expression, HIV infectivity, and
partially restores wild-type HIV integration site distributions.
(A) Western blot showing Transportin-3 levels in cells treated with
TNPO3 si4 in the presence or absence of the Transportin-3 rescue
plasmid. Cells were cotransfected with siRNA and either empty vector
plasmid or rescue plasmid encoding siRNA-resistant alleles of Trans-
portin-3 expressed from the CMV promoter and harvested at 48 hr
post-transfection for analysis. Transportin-3 is reduced after co-
transfection with siRNA and empty vector, and overexpressed after
co-transfection with siRNA and rescue plasmid. Endogenous levels of
Transportin-3 are shown in cells transfected with the control siRNA
targeting GL2 and an empty vector. (B) HIV infection in cells treated
with TNPO3 si4 in the presence or absence of the Transportin-3 rescue
plasmid. Cells were co-transfected as above. 48 hr after transfection
cells were infected with a VSVG-pseudotyped HIV-1 vector carrying a
GFP reporter. At 48 hpi cells were harvested and the percent of cells
expressing GFP was determined by flow cytometry. The Y-axis shows
relative infection compared to infection in the control (GL2 siRNA +
empty vector-transfected) cells. (C) Average gene density in 1 Mb
windows surrounding HIV integration sites in cells depleted or rescued
for Transportin-3 expression. Asterisks denote significant differences as
determined by the Mann–Whitney test (*P,0.05; **P,0.01;
***P,0.001).
doi:10.1371/journal.ppat.1001313.g003
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integration sites increased from 11 (in the presence of TNPO3 si4
and an empty vector) to 14 when Transportin-3 expression was
rescued (p,0.01, Figure 3c). The effect of knockdown in the
presence and absence of rescue on additional genomic features is
described in Text S2. It is unclear why restoring Transportin-3
protein levels did not fully rescue the integration defect, but this
result may be due to the abnormally high levels of Transportin-3
expressed from the siRNA-resistant construct. Nevertheless, these
data support the idea that off-target effects of the TNPO3 siRNA
do not account for the phenotypes observed.
Transportin-3 depletion has no detectable effect on gene
density surrounding MLV integration sites
As a control, we tested whether MLV integration, which
requires cell division for infection and is not dependent on
Transportin-3 [7,39], showed altered integration targeting in the
Transportin-3-depleted cells. We found that treatment with siRNA
targeting TNPO3 mRNA, either in the presence or absence of the
rescue plasmid, did not affect MLV infection efficiency (Figure 4a).
We sequenced MLV integration sites from knockdown and control
cells (Table S1), and found no significant changes in MLV
integration frequency in gene dense regions (Figure 4b), within
transcription units, or with respect to GC content (data not
shown). These data indicate that Transportin-3 depletion does not
affect MLV integration targeting as it does for HIV.
Other nuclear factors may participate in directing
integration to gene dense regions
Integration site data sets were also acquired for cells treated with
siRNAs for NUP98, MAP4, IK, ANAPC2, PRPF38A, SNW1,
WDR46 and WDHD1 (Table S1). For many of these, consider-
able toxicity was detected (Figure S3). Thus interpretation of
integration targeting results for these factors is more tentative than
for Transportin-3 and RanBP2. Data sets were analyzed for their
association with gene density as for Transportin-3 and RanBP2
(Figure 5). Knockdown of several of the factors (ANAPC2, SNW1,
PRPF38, WDH1, and IK) led to decreased integration in gene
dense regions. MAP4 depletion was also seen to modestly decrease
integration preference for gene dense regions in some experiments.
For two of these genes, SNW1 and ANAPC2, we confirmed that
although MLV infection is diminished in the knockdowns as
previously noted [7], the gene density at MLV integration sites is
unchanged (Figure S7), suggesting that, like Transportin-3, the
factors encoded by these genes are potentially involved in targeting
pathways specific for HIV. By contrast, gene density at integration
sites in cells stably depleted of Ledgf was not significantly
decreased compared to the siGL2 control.
For those knockdowns where we could sequence at least 200
integration sites, the global integration site patterns were
investigated by assessing integration frequency relative to many
genomic features for each knockdown, and the patterns were
clustered using a conditional logit model to conduct pairwise
comparisons of the datasets (details are in Text S3). The
dendrogram in Figure 6 shows that the controls clustered in a
group separate from Transportin-3 and RanBP2 knockdowns.
Data sets for several additional gene knockdowns clustered in the
TNPO3/RANBP2 group, including IK, ANAPC2, SNW1,
WDHD1 and PRPF38A. For MAP4 and WDR46 different
siRNAs fell in different groups, and so these have an indeterminate
effect. Thus the IK, ANAPC2, SNW1, WDHD1 and PRPF38A
Figure 4. Depletion of Transportin-3 does not alter MLV integration targeting. (A) Infection levels of MLV in cells co-transfected with the
control siRNA to GL2 plus an empty vector, TNPO3-si4 plus an empty vector, or TNPO3 si4 plus a vector encoding the siRNA-resistant Transportin-3
allele. (B) Average gene density in 1 Mb windows surrounding MLV integration sites in cells depleted or rescued for Transportin-3 expression. No sets
showed significant differences from GL2-treated cells as determined by the Mann–Whitney test.
doi:10.1371/journal.ppat.1001313.g004
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genes encode candidates for additional factors acting in the same
pathway with Transportin-3 and RanBP2. The Ledgf/p75
knockdown was an outlier in the control cluster. This is consistent
with Ledgf/p75 knockdown leading to effects not seen in depletion
of RanBP2, or Transportin-3. For this analysis we investigated
both low MOI (30–60% infected wild type cells) and high MOI
(90–100% infected cells) infections. In most cases the MOI made
no difference on the overall position of a knockdown within the
tree, suggesting that the roles of the factors are not saturable under
the conditions tested.
HIV gag is a determinant of integration targeting to gene
dense regions
We previously studied integration targeting in HeLa cells using
HIV chimeras containing MLV gag, MLV IN, or both, in place of
their HIV counterparts [40]. We found that MLV IN was a
dominant determinant of MLV-like integration, resulting in
integration near transcription start sites by HIV derivatives
containing MLV IN. Similar chimeric viruses have been used to
show that HIV capsid is a dominant viral determinant of HIV
nuclear entry in non-dividing cells [41]. Recently, Lee and
colleagues [34] suggested that the HIV CA protein might
determine the interactions between HIV PICs and nuclear pore
components. These findings led us to reinvestigate integration
targeting by the HIV chimera containing MLV gag in place of
HIV gag (HIVmGag; Fig. 7A) [40]. We found that HIVmGag
showed a shift in distribution of integration sites towards less gene
dense regions compared to the unmodified control (Figure 7B).
The average number of genes within 1 MB of HIVmGag
integration sites was 11 as compared to 20 for the unmodified
HIV control (A Chi square test over ranked comparisons of gene
density values between the two sets attains a p value of ,2.22–16).
A comparison over many genomic features (Figure 7C and Figure
S8) showed a pattern of HIVmGag integration similar to that seen
for HIV in Transportin-3 and RanBP2 depleted cells (compare
Figure 2), including reduced density of genes, CpG islands, DNase
I hypersensitive sites and reduced GC content surrounding
integration sites. Thus substitution of HIV gag with MLV gag
phenocopied the TNPO3 and RANBP2 knockdowns.
Knockdowns of RANBP2 or TNPO3 do not cause HIV to
favor integration near transcription start sites
A model to explain the altered integration site patterns of HIV in
TNPO3 or RANBP2 knockdowns is that in the absence of these
Figure 5. Depletion of additional host factors and their effects on HIV integration in gene dense regions. Integration sites were isolated
from cells treated with siRNAs targeting the indicated genes. The average numbers of RefSeq genes in 1 Mb windows surrounding integration sites
are shown. Data for a given gene knockdown is the average over multiple siRNA knockdowns using different siRNAs and pools of siRNAs targeted to
the same gene, except for Mock, control siRNA (GL2), and LEDGF knockdown conditions for which single treatments were used. Asterisks denote
significant difference from control GL2 siRNA-treated cells as determined by the Mann–Whitney test (*P,0.05; **P,0.01; ***P,0.001). Error bars
represent standard error for biological replicates. For LEDGF only one dataset was available.
doi:10.1371/journal.ppat.1001313.g005
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pore proteins the HIV PIC accesses chromatin during nuclear
breakdown during mitosis. MLV employs such a mechanism for
nuclear entry, so we wondered whether the HIV integration site
distributions in the knockdowns might resemble the normal pattern
for MLV.We asked whether HIV integration in cells knocked down
for TNPO3 and RANBP2 shows the most characteristic feature of
MLV integration, favored integration near transcription start sites
(Figure 8). We found that HIV in the knockdowns disfavors
transcription start sites, paralleling HIV integration in unmodified
cells. MLV showed strongly favored integration in transcription
start sites in the 293T cells studied, and in 293T cells knocked down
for TNPO3. We conclude that obstructing the normal HIV
pathway of integration by knocking down RANBP2 or TNPO3
does not result in an MLV-like integration targeting pattern. This is
consistent with the observation that IN is the dominant determinant
of MLV like integration patterns at transcription start sites for
chimeric viruses where HIV IN is replaced with MLV IN [40,41].
Discussion
Here we report that depletion of Transportin-3 and RanBP2 by
RNAi affects the downstream choice of targets for HIV DNA
integration, providing evidence for coupling of the nuclear transloca-
tion and integration steps. As others have noted, Transportin-3 has
little or no effect on infection efficiency of MLV [6,7,9], which is not
thought to traverse the nuclear pore, and we report that Transportin-3
did not affect integration targeting by MLV. Replacing HIV gag with
MLV gag phenocopied the effects of the Transportin-3 and RanBP2
Figure 6. Dendrogram showing clustering of integration site data sets from knockdowns of Transportin-3, RanBP2, and several
additional factors. Only sets containing at least 200 integration sites were used for the analysis. A conditional logit model was used to cluster
integration sites data sets based on annotation of in or out of annotated transcription units, gene density, expression density, CpG islands, G/C
content, nearby oncogenes, and local sequence features (Text S3). Sets were clustered based on their overall similarity in a pairwise analysis. The
"Control" cluster is so named because it contains the Mock and siGL2 control data sets. Branch labels indicate the siRNA used for the analysis, and
indicates the name of the targeted gene (e.g. TNPO3 si4). Infections were performed using enough HIV vector stock to infect 30–60% of untreated
cells except where marked as ‘‘highMOI’’ where 90–100% of untreated cells were infected.
doi:10.1371/journal.ppat.1001313.g006
Transportin-3 and RanBP2 in HIV Integration
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knockdowns on HIV integration targeting. These findings support a
model in which HIV Gag proteins interact with Transportin-3 and
RanBP2 to mediate HIV integration targeting to chromosomal
regions rich in genes and associated features.
We found that depletion of several additional factors previously
shown to be required for efficient integration also resulted in HIV
integration targeting patterns similar to those seen in Transportin-
3 and RanBP2 depleted cells. These factors include a component
of the anaphase promoting complex (ANAPC2) splicing factors
(SNW1 and PRPF38), a WD-repeat protein (WDHD1), and
nuclear DNA binding proteins (IK and SNW1). The analysis of
some of these was complicated by cell toxicity, and in some cases
conflicting results were obtained with different siRNAs, so effects
of these factors are less well supported than those of Transportin-3
and RanBP2. It is possible that each of these factors acts in a
common pathway with Transportin-3 and RanBP2 to direct
integration to regions dense in genes and associated features,
though depletion of some of these factors could also alter the
synthesis or function of other factors acting more directly.
Our studies support the hypothesis that nuclear import of HIV is
linked to integration, and suggest that normal interactions with the
nuclear pore help to determine integration target site distributions
(Figure 9). We favor a two-step model, in which passage through the
pore first places the PIC in regions of high gene density, and then
Ledgf/p75 tethers the PIC for integration to provide the final
distribution in active transcription units. Several studies suggest that
chromosomes and genes are nonrandomly distributed in the
nucleus, though the organization is not fully clarified [42–44].
Although the nuclear periphery is thought to be rich in
heterochromatic chromosomal regions that promote gene silencing,
studies in yeast and Drosophila suggested that genes can relocate to
the nuclear pore upon transcriptional induction [45–50]. Thus
passage through the pore may deliver HIV to locally concentrated
active gene-dense chromatin. Alternatively, interaction with
Transportin-3 and RanBP2 at the pore might engage a nuclear
transport system leading to gene-dense chromatin.
Our data is consistent with the idea that correct engagement
of the Transportin-3/RanBP2-dependent targeting pathway
leads to efficient integration in chromosomal regions rich in
genes and associated features. Failure to engage this pathway
results in targeting to less gene dense regions. Two possible
scenarios can be imagined for nuclear entry and integration
Figure 7. A chimeric derivative of HIV containing MLV gag (HIVmGag) shows reduced integration frequency in gene dense regions.
(A) Genetic map of HIV proviruses containing wild type gag (HIVPuro) or a chimera encoding MLV Gag (MA, p12, and CA) in place of HIV MA and CA
(HIVmGag). Both viruses have inactivated vpr and env and a puromycin selectable marker in place of nef. (B) Histogram indicating distribution of
HIVPuro and HIVmGag integration sites with respect to gene density measured in 1 Mb intervals surrounding integration events. Data is plotted as in
Fig. 1C and curves are computed using Gaussian kernel density estimates. (C) Genomic heatmap of HIVPuro and HIVmGag datasets. Significant
differences are shown by asterisks (*p,0.05; **p,0.01; ***p,0.001). Annotations at the left of the heat map are as in Figure 2 and described in Text
S1. An interactive version of this figure is available as Figure S8.
doi:10.1371/journal.ppat.1001313.g007
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targeting in cells depleted for pore factors Transporting-3 and
RanBP2.
The first model is that in the absence of Transportin-3 or RanBP2,
nuclear access of HIV is restricted to times of nuclear envelope
breakdown during cell division. The shift in integration away from
gene-dense regions in the TNPO3 and RANBP2 knockdowns may
thus reflect changes in chromatin availability during mitosis or
shortly afterwards. Consistent with this idea, the HIVmGag virus
requires nuclear envelope breakdown during mitosis for infection
[41], and it phenocopied HIV integration in the knockdown cells,
showing reduced integration frequency in gene dense regions.
An extreme version of this model would hold that HIV
integration targeting in TNPO3 and RANBP2 knockdowns might
mimic MLV targeting because in both cases the virus accesses
chromatin during nuclear breakdown. However, MLV strongly
favors integration near transcription start sites, and this is not seen
for HIV in knockdown cells (Figure 8).
Similarly, if passage through the nuclear pore delivers the HIV
PIC to transcription units and gene dense regions, growth arrest of
cells might increase favoring of these features, since all integrants
must enter through the pore in arrested cells. Integration site
distributions have been investigated in growth arrested IMR90
lung fibroblasts and macrophages [28,51]. In IMR90 cells, arrest
did result in more integration in transcription units and gene dense
regions, but in macrophages the favoring is in fact weaker than
that observed in many other cell types [27]. Thus it is possible that
passage through the nuclear pore results in favored integration in
gene dense regions, but additional assumptions are needed to
explain the data from macrophages.
The second model (not exclusive of the first) holds that in cells
depleted of TNPO3 and RanBP2, HIV integration complexes may
pass through the pore but on a different pathway, interacting with
different pore proteins. The idea that alternative pathways through the
pore exist is supported by findings of Lee and colleagues, who found
that the N74D substitution in HIV CA disrupted normal interactions
with Transportin-3 and RanBP2 but created dependence on other
pore proteins [34]. From our data, it is not possible to determine
whether in cells depleted of Transportin-3 and RanBP2 HIV
integration complexes pass through the pore on alternate pathways,
or whether nuclear access during mitosis fully explains the data. Thus it
will be important to analyze targeting when integration complexes pass
through the pore on alternative pathways, as in the presence of the
N74D CA substitution (Schaller et al., submitted).
Materials and Methods
Cell culture and viral infections
HEK 293T cells were grown in D10 media (DMEM
supplemented with 10% FBS and 50 ug/mL Gentamicin). For
gene knockdowns, cells were grown to confluency, trypsinized and
reverse transfected (100,000 cells/well in 12 well plates, 50,000/
well in 24 well plates, and 8,000/well in 96 well plates) using
Figure 8. HIV and MLV integration patterns at transcription start sites are unaffected by knockdown of TNPO3 or RANBP2. The
percent of integration sites within the indicated genomic distances (kb) from the transcription start site (RefSeq genes) is plotted for each dataset.
Sample names indicate the VSVG-pseudotyped viral vector used (HIV or MLV) followed by the cell treatment (either control siGL2 or gene-specific
siRNA used).
doi:10.1371/journal.ppat.1001313.g008
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RNAiMax (Invitrogen, Carlsbad CA) with 25 pmol/mL siRNA.
The siRNAs were purchased from Qiagen (Qiagen, Valencia, CA)
and are listed in Table S2. Toxicity of siRNAs was measured 48 hr
after transfection both visually and by the CellTiter-Glo
Luminescent Cell Viability Assay (Promega, Madison WI; see
Figure S3 for details). Transfection media was replaced after 48 hr
by 500 mL of D10 plus 5 ug DEAE dextran and virus in 12 well
plates. Two viral inoculums were used (0.06 mL or 1 mL
concentrated virus stock corresponding to 1.32 ng or 22 ng p24
per well, values determined by titration to result in infection of 30–
60% or 80–100% of cells, respectively). Virus-containing media
was replaced after 10–12 hours with 1 mL D10 and incubated
an additional 38 hours before harvest. Infections of LEDGF
stable knockdown cell lines were performed essentially as described
[28].
VSV-G pseudotyped HIV vector particles were produced in
HEK 293T cells by Lipofectamine (Invitrogen, Carlsbad CA)
transfection of p156RRLsin-PPTCMVGFPWPRE [52], the
packaging construct pCMVdeltaR9 [53], and the vesicular
stomatitis virus G-producing plasmid pMD.G. VSV-G pseudo-
typed MLV particles were produced in a similar manner but using
the MLV vector segment (pMX-eGFP) and packaging construct
pCGP (pCGP, kindly provided by Paul Bates).
Percent infection was measured using GFP fluorescence,
which is not strongly affected by integration site placement in
the HIV-based vectors with strong artificial promoters used
here [30].
HIV infection and targeting rescue experiments were performed
as described for siRNA knockdowns but with the co-transfection of
siRNA-resistant or empty expression vectors (333 ng plasmid/
mL). The siRNA-resistant TNPO3 allele was constructed by
introducing six conservative mutations in the third position of each
codon and an N-terminal 3xFLAG-tag into the TNPO3 cDNA
amplified HEK-293T cells. This product was then cloned into the
mammalian expression vector pLNCX (kind gift of Paul Bates),
engineered to contain a WPRE.
Gene expression by RNA and protein levels
Q-PCR (see Figure S1 for details) and immunoblotting were
used to monitor the extent of siRNA knockdowns. Protein levels
were measured by immunoblotting using antibodies against
Transportin-3 (ab54353, Abcam Inc., Cambridge, MA) and
RanBP2 (ab2938, Abcam Inc., Cambridge, MA). HRP
conjugated secondary antibodies (p0260, DAKO A/S, Den-
mark, and ab6721-1, Abcam, Cambridge, MA) were used for
detection with SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientific, Pierce Protein Research Products,
Rockford, IL). Beta-tubulin was used as a loading control,
detected by the HRP conjugated antibody (ab21058, Abcam,
Cambridge, MA).
Integration site analysis
For integration site recovery, purified genomic DNA was
digested overnight with MseI, ligated at 16uC to PCR adapters,
and digested a second time with SacI. Nested PCR was then
performed using primers and conditions described previously
[36,54]. Amplification products between 200–600 bp were then
gel-excised, purified, and sequenced on a Genome Sequencer FLX
Titanium Series (Roche 454 Sequencing) at either the University
of Pennsylvania or the University of Florida. Only sequences that
began within three base pairs of the LTR end and showed unique
best alignments to the human genome by BLAT (hg18, version
36.1, .98% match score) were considered true integration sites.
Identical integration sites identified in two or more separately
amplified samples were considered to be PCR contamination and
were omitted.
Comparisons to genomic features were carried out as described
previously [18,55] using a combination of conditional logit
regression and Bayesian model averaging. Details of statistical
methods are available in [14,18,55,56]. Methods used for
statistical analysis of ROC areas (Figures 3 and 8) are summarized
in [56]. Gene expression analyses utilized data from 293T cells
[28] with expression measured using the Affymetrix HU133 plus
Figure 9. Model for coupling of nuclear import and integration
targeting. Interaction with Transportin-3 and RanBP2 shuttles the PIC
through the nuclear pore and toward gene dense regions favored for
HIV integration. Interactions with additional factors in the nucleus
(ANAPC2, WDH1, IK, PRPF38A, and SNW1) may also play a role in site
selection upstream of the known integration cofactor Ledgf/p75, which
targets integration to active transcription units. RNA Pol indicates RNA
polymerase II, which is known to be required for transcriptional activity,
and which promotes integration [13–15,18]. Nucleosomes are shown
because target DNA is known to be wrapped in nucleosomes during
the integration step [36,57–60]. PIC, preintegration complex; FG,
phenylalanine-glycine repeat sequences of nuclear pore proteins.
doi:10.1371/journal.ppat.1001313.g009
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2.0 gene chip array. All integration site sequences will be deposited
in publicly accessible databases (NCBI) upon acceptance of this
manuscript for publication.
Entrez Gene ID numbers for genes mentioned in the text
NUP98: 4928, MAP4: 4134, IK: 3550, ANAPC2: 29882,
PRPF38A: 84950, RANBP2/NUP358: 5903, SNW1: 22938,
TNPO3: 23534, WDR46: 9277, WDHD1:11169, PSIP1/
LEDGF/p75: 493969.
Supporting Information
Figure S1 mRNA levels under normal and gene knockdown
conditions. 293T cells were reverse transfected as described in
Materials and Methods (8,000/well in 96 well plates using
RNAiMax (Invitrogen, Carlsbad CA) with 25 pmol/mL siRNA,
then incubated 48 hr at 37uC before harvest. RNA was purified
from cells using either the RNeasy Mini Kit from Qiagen
(Carlsbad, CA) or the RNAspin Mini Kit (GE Healthcare,
Buckinghamshire UK) per manufacturer’s instructions. RT-PCR
was carried out using the High Capacity RNA to cDNA Kit
(Applied Biosystems, Foster City CA) and relative RNA levels were
measured by the ddCt method using Taqman Gene Expression
Assays (Applied Biosystems, Foster City CA) with GUSB as the
internal reference. Assays IDs were Hs00193785_m1, Hs006-
00887_m1, Hs00173172_m1, Hs00273527_m1, Hs00159048_m1,
Hs00610583_m1, Hs01108576_m1, Hs00203499_m1, Hs0027-
3351_m1, Hs00180522_m1 for genes measured for knockdown
and product number 4333767F for the GUSB endogeneous control
assay. All values were normalized the control siRNA, GL2. Data
presented is representative of at least three replicate experiments.
Found at: doi:10.1371/journal.ppat.1001313.s001 (1.58 MB TIF)
Figure S2 HIV infection levels under normal and gene
knockdown conditions. 48 hr following siRNA transfection, media
was replaced with 500 mL of D10 (12 well plates) plus 5 ug DEAE
dextran and virus as described in Materials and Methods (0.06 mL
concentrated virus stock corresponding to 1.32 ng p24 per well,
innoculum determined by titration to result in infection of 30–60%
of cells). Virus-containing media was replaced after 10–12 hours
with 1 mL D10 and incubated an additional 38 hours before
harvest. Infection level was measured by flow cytometry as the
percentage of GFP positive cells. All values normalized to Mock
controls.
Found at: doi:10.1371/journal.ppat.1001313.s002 (0.77 MB TIF)
Figure S3 Cell viability after siRNA transfection. Toxicity of
siRNAs was measured 48 hr after transfection both visually and by
the CellTiter-Glo Luminescent Cell Viability Assay (Promega,
Madison WI) following the manufacturer’s instructions. Cells were
reverse transfected in 96 well plates with the indicated siRNAs at
25 pmol/ml final concentration and incubated at 37uC. All values
normalized to GL2 controls. Data shown is representative of at
least two independent experiments.
Found at: doi:10.1371/journal.ppat.1001313.s003 (1.49 MB TIF)
Figure S4 SNW1 protein levels under normal and gene
knockdown conditions. Cells were reverse transfected with
SNW1 si5 or with GL2 as described, incubated 48 hr, harvested,
and lysed for protein analysis. Blotting was done using rabbit
polyclonal antibody from Santa Cruz Biotechnology (Santa Cruz,
CA; product SC-30139 Lot B1506). Following gel transfer, PVDF
membranes were incubated 2.5 hr at RT (antibodies diluted
1:2000 in PBST, 5% milk) followed by incubation for 1 hr at RT
with secondary antibody was Abcam HRP conjugated Goat anti
Rabbit (goat polyclonal to Rabbit IgG; ab6721-1 lot 142201,
diluted 1:2000 in PBST, 5% milk). Knockdown of protein levels
for ANAPC2 could not be confirmed by western blot (Abcam,
product ab18295).
Found at: doi:10.1371/journal.ppat.1001313.s004 (1.12 MB TIF)
Figure S5 Effects of Transportin-3 and RanBP2 depletion on
integration near multiple chromosomal features: interactive heat
map. Data was analyzed and is displayed as described in Figure 2
and Text S1. To view, download and open zip file, and follow
instructions in the included ReadMe.txt document.
Found at: doi:10.1371/journal.ppat.1001313.s005 (0.21 MB ZIP)
Figure S6 Partial rescue of HIV integration site distributions by
Transportin-3 allele insensitive to TNPO3 si4. Cells were
cotransfected with siRNA and either empty vector plasmid or
rescue plasmid encoding siRNA-resistant alleles of Transportin-3,
infected with a VSVG-pseudotyped HIV-1 vector, and harvested
for integration site analysis as described. Histogram shown indicates
distribution of integration sites with respect to gene density.
Integration sites in each dataset were binned (along the X-axis)
according to the number of genes within 1 MB interval surrounding
each site (counted as shown in Figure 1B). Curves were computed
from histogram plot using Gaussian kernal density estimates.
Found at: doi:10.1371/journal.ppat.1001313.s006 (1.15 MB TIF)
Figure S7 MLV infection and integration site distributions after
siRNA treatment targeting SNW1 and ANAPC2. MLV infections
were carried out using VSV-G pseudotyped, single round viral
vectors in the same manner described for HIV infections (see
Materials and Methods and Supplementary Figure 2). Infection
level was measured by flow cytometry as the percentage of GFP
positive cells. All values normalized to GL2 controls.
Found at: doi:10.1371/journal.ppat.1001313.s007 (1.54 MB TIF)
Figure S8 Effects of MLV-Gag swap on integration near
multiple chromosomal features: interactive heat map. Data was
analyzed and is displayed as described in Figure 7c and Text S1.
To view, download and open zip file, and follow instructions in the
included ReadMe.txt document.
Found at: doi:10.1371/journal.ppat.1001313.s008 (0.29 MB ZIP)
Table S1 Integration site data sets used in this study.
Found at: doi:10.1371/journal.ppat.1001313.s009 (0.08 MB PDF)
Table S2 DNA and RNA oligonucleotides used in this study.
Found at: doi:10.1371/journal.ppat.1001313.s010 (0.08 MB PDF)
Text S1 Guide to Interpreting Genomic Heat Maps Summa-
rizing Integration Site Distributions.
Found at: doi:10.1371/journal.ppat.1001313.s011 (0.12 MB PDF)
Text S2 Distributions of HIV integration sites after TNPO3
knockdown and rescue with siRNA insensitive allele.
Found at: doi:10.1371/journal.ppat.1001313.s012 (0.58 MB PDF)
Text S3 Integration site preference under gene silencing.
Found at: doi:10.1371/journal.ppat.1001313.s013 (1.33 MB PDF)
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